Therapeutic-focused CRO Services

KCAS Bio has proven expertise across a range of disease and treatment areas. With more than 45 years of experience as a drug development CRO, we combine deep bioanalytical and biomarker experience with our reputation for consistency, transparency, and data integrity at every stage of your specific therapeutic focus area.

Talk to an expert

Therapeutic areas of focus

Allergy & immunology

We have extensive experience in developing, validating, and implementing immunological methods, including biomarker quantification and flow cytometry. Trust our team of experts to provide tailored solutions for your drug development needs.

Explore now
Oncology

KCAS Bio provides reliable data to advance immune-oncology treatments. From discovery to Phase III trials, we have experience in flow cytometry, ELISPOTs, and cell-based assays, alongside multiple biomarkers.

Explore now
Infectious diseases

In a post-COVID-19 world, trust a CRO with proven experience in infectious disease and vaccine development. KCAS stands ready, equipped with diverse platforms and techniques for your project success.

Explore now
Neurological

In a world witnessing a surge in brain disorders, our advanced neurosciences expertise is your ally from discovery to translation. Unlock the potential of neurological drug development with KCAS.

Explore now
Gastrointestinal

With a focus on experimental therapeutics, we address a spectrum of conditions including Crohn's disease and inflammatory bowel disease. Trust KCAS for a comprehensive approach to advance your project in the evolving landscape of gastrointestinal disorders.

Explore now
Ophthalmology

From compound identification to efficacy studies, we specialize in preclinical ophthalmic research. Our experienced team ensures milestone data accuracy for crucial early-stage decisions. Trust KCAS Bio for the complexities of your ophthalmology study.

Explore now
Rare diseases

Our validated 20-plex assay for 20 amino acids supports metabolism and rare disease research. Developing drugs for rare diseases demands specialized expertise, especially in cell and gene therapy. KCAS Bio stands out with a proven history and experience.

Explore now
Respiratory

We monitor immune system status during and after infection, offering flow cytometric immunophenotyping, cytokine profiling, and retrospective studies. With expertise in whole blood, PBMCs, and respiratory samples, we specialize in diseases like COPD, lung cancer, and pneumonia.

Explore now
Renal

Trust KCAS for expert renal/kidney testing. We develop assays, even for challenging compounds, ensuring quality data for drug development. With extensive experience, we understand the crucial role renal function plays in drug elimination.

Explore now
Cardiovascular

With 40+ years in pre-clinical research, we provide deep expertise in cardiovascular biomarkers and large molecule drugs. From target identification to drug development, trust us for comprehensive bioanalytical support at every stage of your cardiovascular drug project.

Explore now
Metabolic

Discover comprehensive support for metabolic drug development with KCAS. With a deep understanding of metabolic and endocrine diseases, we provide expert bioanalytical services from discovery to biologic development.

Explore now

Find exactly what you’re looking for

Search for specific services, platforms, instrumentation, or scientific insights.

Quantification of antibody–drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies Posters & Papers
Read article Quantification of antibody–drug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies

This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method…

Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies Posters & Papers
Read article Quantitation of total antibody (tAb) from antibody drug conjugate (ADC) PYX-201 in rat and monkey plasma using an enzyme-linked immunosorbent assay (ELISA) and its application in preclinical studies

This case study describes the development and validation of an ELISA method to quantify total antibody (tAb) from PYX-201, an investigational antibody-drug conjugate (ADC) developed by Pyxis Oncology. The assay was validated in rat and monkey plasma and used to support preclinical studies and an IND filing. The method…

Updated Recommendations for the Bioanalysis of Antibody–Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community Posters & Papers
Read article Updated Recommendations for the Bioanalysis of Antibody–Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community

This article provides updated recommendations for the bioanalysis of antibody-drug conjugates (ADCs), reflecting more than a decade of advances in the field. Developed by the AAPS ADC Working Group, it addresses key considerations for quantifying total antibody, conjugated ADC, free payload, and drug-to-antibody ratio (DAR), as well as immunogenicity,…

Agile, responsive, and easy to work with

We prepare and adapt our services based on a deep understanding of your drug development ambitions and wider business objectives.

Explore services